Mulpleta approved in China to treatthrombocytopenia in adult patients with chronic liver disease – Eddingpharm

Shionogi announced that its Chinese license partner Eddingpharm has won regulatory approval for its thrombopoietin receptor agonist Mulpleta (lusutrombopag) in China. The drug was approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an elective invasive procedure. Originated by Shionogi, Mulpleta is a small molecule agonist of the human thrombopoietin […]